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DEFINITION 
 Pulmonary 
embolism (PE) is a 
blockage of the 
pulmonary artery or 
one of its branches, 
usually occuring when a 
venous thrombus 
becomes dislodged from 
its site of formation and 
embolizes to the arterial 
blood supply of one of 
the lungs 
 
https://slideplayer.com/slide/7254533/ 
EPIDEMIOLOGY 
 Venous thromboembolism (VTE) 
encompasses deep vein thrombosis (DVT) and 
pulmonary embolism (PE) 
 It is the third most frequent cardiovascular 
disease with an overall annual incidence of 
100–200 per 100 000 inhabitants 
 VTE may be lethal in the acute phase or lead 
to chronic disease and disability, but it is also 
often preventable 
https://www.portailvasculaire.fr/sites/default/files/docs/2014_esc_guidelines_ep_eurheartj-ehu283.pdf 
 The epidemiology of PE is difficult to determine 
because it may remain asymptomatic, or its 
diagnosis may be an incidental finding;  
in some cases, the first presentation of PE may 
be sudden death 
EPIDEMIOLOGY 
https://www.portailvasculaire.fr/sites/default/files/docs/2014_esc_guidelines_ep_eurheartj-ehu283.pdf 
PREDISPOSING FACTORS 
HYPERCOAGULABILITY  
 Cancer 
 Pregnancy 
 Postpartum status(<4 wks) 
Oral contraception 
 Antiphospholipid antibodies 
 Genetic mutations 
– Factor V Leiden mutation 
– Prothrombin gene mutation 
– Factor VIII mutations 
– Protein C deficiency 
– Protein S deficiency 
VENOUS STASIS 
 Bed rest >48 hrs 
 Cast or external fixator 
 Recent hospitalization 
 Long distance automobile 
or air travel 
https://www.portailvasculaire.fr/sites/default/files/docs/2014_esc_guidelines_ep_eurheartj-ehu283.pdf 
 
VESSEL INJURY 
 Recent surgery requiring 
endotracheal intubation 
 Recent trauma requiring 
hospitalization 
 
 PATHOPHYSIOLOGY 
http://deko4halloweenguenstig.info/dvt-drug-treatment-2018-46fdc/ 
 PATHOPHYSIOLOGY 
Key factors 
contributing to 
haemodynamic 
collapse in acute 
pulmonary 
embolism 
https://www.portailvasculaire.fr/sites/default/files/docs/2014_esc_guidelines_ep_eurheartj-ehu283.pdf 
PE: 
SYMPTOMS 
https://www.portailvasculaire.fr/sites/default/files/docs/2014_esc_guidelines_ep_eurheartj-ehu283.pdf 
CLINICAL CHARACTERISTICS OF 
PATIENTS WITH SUSPECTED PE IN THE 
ER 
https://www.portailvasculaire.fr/sites/default/files/docs/2014_esc_guidelines_ep_eurheartj-ehu283.pdf 
INITIAL RISK STRATIFICATION OF 
ACUTE PE 
 a Defined as systolic 
blood pressure (SBP) 
< 90 mm Hg, or a 
systolic pressure drop 
by ≥40 mm Hg, for 
>15 minutes, if not 
caused by new-onset 
arrhythmia, 
hypovolaemia, or 
sepsis 
 b Based on the 
estimated PE-related 
in-hospital or 30-day 
mortality 
 
https://www.portailvasculaire.fr/sites/default/files/docs/2014_esc_guidelines_ep_eurheartj-ehu283.pdf 
PE: CLINICAL PROBABILITY 
 
https://www.portailvasculaire.fr/sites/default/files/docs/2014_esc_guidelines_ep_eurheartj-ehu283.pdf 
PE: CLINICAL PROBABILITY 
 
https://www.portailvasculaire.fr/sites/default/files/docs/2014_esc_guidelines_ep_eurheartj-ehu283.pdf 
DIAGNOSTIC ALGORITHM 
https://www.portailvasculaire.fr/sites/default/files/docs/2014_esc_guidelines_ep_eurheartj-ehu283.pdf 
DIAGNOSTIC ALGORITHM 
https://www.portailvasculaire.fr/sites/default/files/docs/2014_esc_guidelines_ep_eurheartj-ehu283.pdf 
ELECTROCARDIOGRAPHIC FINDINGS IN 
PULMONARY EMBOLISM 
ECG shows an S1Q3T3 pattern 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4613926/ 
TREATMENT 1.4. 
1)Haemodynamic 
and respiratory 
support 
 Use of vasopressors 
is often necessary 
(Epinephrine) 
 Administration of 
oxygen 
2)Anticoagulation 
 Parenteral 
anticoagulation 
(intravenous UFH, 
subcutaneous 
LMWH, or 
subcutaneous 
fondaparinux) 
https://www.portailvasculaire.fr/sites/default/files/docs/2014_esc_guidelines_ep_eurheartj-ehu283.pdf 
Low molecular weight heparin and pentasaccharide 
(fondaparinux) approved for the treatment of PE 
TREATMENT 2.4. 
2) Anticoagulation 
 Vitamin K antagonists (should be initiated as 
soon as possible, and preferably on the same day 
as the parenteral anticoagulant) 
 Warfarin (under international normalized ratio 
(INR) control-target 2.0-3.0). 
 
Started at a dose of 10 mg in younger (e.g. ,60 years 
of age), otherwise healthy outpatients, and at a dose 
of 5 mg in older 
https://www.portailvasculaire.fr/sites/default/files/docs/2014_esc_guidelines_ep_eurheartj-ehu283.pdf 
TREATMENT 3.4. 
2)Anticoagulation 
New oral anticoagulants 
https://www.portailvasculaire.fr/sites/default/files/docs/2014_esc_guidelines_ep_eurheartj-ehu283.pdf 
Drug Dosage  
Dabigatran  150 mg b.i.d 
Rivaroxaban 15 mg b.i.d. for 3 weeks, then 
20 mg o.d 
Apixaban 10 mg b.i.d. for 7 days, then 5 
mg b.i.d. 
Edoxaban (60 mg o.d.; 30 mg o.d. if 
creatinine clearance 30–50 
ml/min or body weight  
b.i.d. ¼ bis in die (twice daily) 
TREATMENT 4.4. 
3) Thrombolytic treatment (streptokinase, 
urokinase, tenecteplase, t recombinant tissue 
plasminogen activator); 
4) Surgical embolectomy 
5) Percutaneous catheter-directed 
treatment 
6) Venous filters (usually placed in the 
infrarenal portion of the inferior vena cava) 
https://www.portailvasculaire.fr/sites/default/files/docs/2014_esc_guidelines_ep_eurheartj-ehu283.pdf 
CAUSES: NON-THROMBOTIC PE 
https://erj.ersjournals.com/content/34/2/452 
FAT EMBOLISM 
• Fat embolism syndrome (FES) is a rare clinical 
consequence of FE, typified by the triad of pulmonary 
distress, mental status changes and a petechial 
rash occurring typically 12–36 hours after injury 
• FE is not limited to skeletal injury 
• It is the leading cause of respiratory deterioration in 
blast victims who survive  
• Among the haemoglobinopathies, SCD is commonly 
associated with pulmonary consequences 
https://erj.ersjournals.com/content/34/2/452 
FAT EMBOLISM 
https://www.alamy.com/development-of-fat-embolism-image7710091.html 
CLINICAL SIGNS FA 
The clinical diagnosis of FES is one of exclusion, supported by 
laboratory and radiological investigations 
MAJOR 
 respiratory distress 
 cerebral involvement 
unrelated to head injury 
 petechial rash on the 
anterior surfaces of the 
neck, thorax or mucous 
membranes 
MINOR 
 tachycardia 
 pyrexia 
 retinal and urinary changes 
(anuria, oliguria or fat globules)  
 laboratory features including 
anaemia, thrombocytopenia or 
high erythrocyte 
sedimentation rate 
https://erj.ersjournals.com/content/34/2/452 
DIAGNOSIS 
Diagnosis is facilitated by the presence of 
haematological and biochemical abnormalities 
Fat globules can be found in blood, urine, sputum, 
bronchoalveolar lavage (BAL) or even 
cerebrospinal fluid 
Induced sputum analysis is also a safe and 
noninvasive test to detect FE in SCD  
In the early stage, atypical radiological findings are 
bilateral lung infiltrates (chest radiography) or 
consolidation and ground-glass opacities 
(computed tomography (CT)) 
https://erj.ersjournals.com/content/34/2/452 
TREATMENT 
 Treatment of FE should primarily be focused on prevention 
 Early immobilisation, open reduction and internal fixation of 
fractures have reduced the incidence of FE 
 FES is largely self-limiting and is usually associated with a good 
outcome 
 Current treatments are supportive: adequate oxygenation as well 
as haemodynamic stability, nutrition and prophylaxis of venous 
thrombosis and stress-related gastrointestinal bleeding  
  A beneficial effect of 7.5 mg·kg−1methylprednisolone given six 
times hourly for 3 days in patients at risk for FES has been 
reported 
  However, the true beneficial effect of corticosteroids either 
before or after the development of symptoms has not been 
shown in a well-designed trial 
https://erj.ersjournals.com/content/34/2/452 
AMNIOTIC FLUID EMBOLISM (AFE) 
The incidence 
of AFE ranges 1 
in 6,000–
120,000 
AFE usually 
occurs during 
the immediate 
postpartum 
period 
pregnancies  
https://www.pulmonologyadvisor.com/home/decision-support-in-medicine/pulmonary-medicine/nonthrombotic-pulmonary-embolism-air-amniotic-fluid-fat-tumor/ 
AMNIOTIC FLUID EMBOLISM (AFE) 
Identified risk factors include: 
 Older maternal age 
 Multiparity 
 Intense contractions during labor 
 Abdominal trauma 
 Cesarean section 
 Induction of labor 
 Placenta previa 
 Eclampsia 
 Multiple pregnancy 
 Early separation of the placenta from 
the uterus wall 
Fetal factors: 
• Fetal distress 
• Fetal death 
• Male baby 
 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874066/ 
PATHOPHYSIOLOGY  
Poorly understood 
Proposed a biphasic model 
Phase 1: 
Amniotic fluid and fetal cells enter the maternal 
circulation→ biochemical mediators →pulmonary artery 
vasospasm → pulmonary hypertension → elevated right 
ventricular pressure → hypoxia→ myocardial and 
pulmonary capillary damage → left heart failure → acute 
respiratory distress syndrome 
Phase 2: 
→ biochemical mediators → DIC→ Hemorrhagic phase 
characterized by massive hemorrhage and uterine atony 
 
https://www.pulmonologyadvisor.com/home/decision-support-in-medicine/pulmonary-medicine/nonthrombotic-pulmonary-embolism-air-amniotic-fluid-fat-tumor/ 
CLINICAL PRESENTATION 
The classic clinical presentation of the syndrome 
has been described by five signs that often occur 
in the following sequence: 
 Respiratory distress 
 Cyanosis 
 Cardiovascular collapse cardiogenic shock 
 Hemorrhage 
 Coma 
https://www.pulmonologyadvisor.com/home/decision-support-in-medicine/pulmonary-medicine/nonthrombotic-pulmonary-embolism-air-amniotic-fluid-fat-tumor/ 
DIAGNOSIS 
AFE is again a diagnosis of exclusion 
Four criteria must be present to make the 
diagnosis of AFE: 
 Acute hypotension or cardiac arrest 
 Acute hypoxia 
 Coagulopathy or severe hemorrhage in the 
absence of other explanations 
 All of these occurring during labor, cesarean 
delivery, dilation and evacuation, or within 30 min 
postpartum with no other explanation of findings 
 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874066/ 
DIAGNOSIS 
 Continuous pulse oximetry and arterial blood gas  
 Serial complete blood counts and coagulation studies  
 The chief radiographic abnormalities in AFE are diffuse bilateral 
heterogeneous and homogeneous areas of increased opacity, 
which are indistinguishable from acute pulmonary edema 
 A 12-lead ECG 
 Lung scan may demonstrate some areas of reduced radioactivity 
in the lung field 
 Increased serum tryptase, urinary histamine 
concentrations and significantly lower complement 
concentrations suggest an anaphylactoid process 
• Few studies have evaluated the diagnostic accuracy of serum 
sialyl Tn (STN), a fetal antigen present in meconium and 
amniotic fluid, detected through the use of TKH-2 monoclonal 
antibody 
 
 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874066/ 
TREATMENT 1.2. 
General 
Maintaining vital signs 
 The initial goal is the rapid correction of maternal 
hemodynamic instability (correction of hypoxia 
and hypotension) 
 Correcting coagulopathy — Blood and blood 
products, including fresh frozen plasma (FFP), 
platelets and cryoprecipitate, must be available 
and administered early in the resuscitation phase 
of AFE 
 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874066/ 
TREATMENT 2.2. 
Pharmacological 
 Epinephrine may be the first-line agent of choice  
 Inotropic support like dopamine or noradrenaline  
 Hydrocortisone 
 Oxytocin: decreases inflammation by suppressing 
migration of polymorphonuclear leukocytes and 
reversing increased capillary permeability 
 Other antifibrinolytic drugs, such as aminocaproic acid 
and tranexamic acid 
 
 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874066/ 
TUMOR EMBOLISM (TE) 
Pulmonary intravascular tumor emboli are 
seen in up to 26% of autopsies of patients 
with solid malignancies, although the 
diagnosis is rarely made before death 
Carcinoma of the prostate gland, 
digestive system, liver, and breast is 
most commonly implicated 
https://www.portailvasculaire.fr/sites/default/files/docs/2014_esc_guidelines_ep_eurheartj-ehu283.pdf 
TE: Pathophysiology 
Macroembolism is a feature of primary tumor 
sites that are connected by the vena cava to the 
right ventricle  
Tumor emboli possess an unusual level of 
resistance to recanalization and are therefore 
more likely to lead to progressive, irreversible 
obstruction 
Most cases of microembolism show a vascular 
tissue reaction with intimal proliferation and 
fibrosis 
https://erj.ersjournals.com/content/34/2/452 
TE:CLINICAL SIGNS 
TE suspected in patients: 
• complain of unexplained dyspnoea and 
developed cor pulmonale 
The most common symptom is subacute 
progressive dyspnea which occurs in 57–
100% of cases over a span of weeks to 
months  
https://erj.ersjournals.com/content/34/2/452 
TE DIAGNOSIS 
 Even in patients known to have a malignancy, 
the correct diagnosis is made in as few as 
6% ante mortem  
 TE has a lack of specific radiological features 
and mimics pneumonia or interstitial lung 
disease 
 A normal chest radiograph with hypoxemia in 
a patient with a malignancy might even suggest 
the presence of TE 
https://erj.ersjournals.com/content/34/2/452 
TE TREATMENT 
 The prognosis is poor and the median survival 
from diagnosis is a few weeks 
 Surgical cure by resection of the primary 
tumor has been reported in patients with atrial 
myxoma, renal cell carcinoma and 
choriocarcinoma 
 Chemotherapy is rarely indicated, although 
favourable results have also been reported in 
patients with choriocarcinoma and breast cancer  
https://erj.ersjournals.com/content/34/2/452 
Case Report 1.10. 
• A 30‐year‐old female working as a courier and 
previously well was referred to the facility with 
acute onset of severe dyspnoea and central 
chest pain 
• She presented with a 4‐day history of dry cough 
and malaise, which had not responded to 
prescribed antibiotics. 
• There were no known risks for PTE; history of 
preceding loss of consciousness, trauma, weight 
loss, or fever; or significant past personal and 
family medical histories 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167281/ 
Case Report 2.10. 
The findings on examination 
• Tachycardia (120 beats/min) 
• Tachypnea (32 breaths/min) 
• Hypoxia on room air 
• Normal blood pressure 
• Apyrexia 
• The chest and cardiac exam findings were 
unremarkable, apart from an accentuated second 
heart sound 
 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167281/ 
Case Report 3.10. 
• Arterial blood gas analysis showed a mild 
respiratory alkalosis  
• Her ECG showed a sinus tachycardia and features 
of right ventricular strain 
• The rapid HIV antibody test was negative and 
CBC, liver function tests, urea, creatinine, 
electrolytes, and INR were normal 
• The D‐dimer was 0.34 mg/L (normal < 0.25 mg/L), 
fibrinogen was 1.2 mg/L (range: 2.0–4.0 mg/dL), 
and the C‐reactive protein was mildly elevated 
 
 
 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167281/ 
Case Report 4.10. 
• An ECHO showed severely dilated right heart 
chambers with elevated right ventricular systolic 
pressures of 115 mmHg (range: 15–25 mmHg) 
and moderately impaired right ventricular systolic 
function 
• The pulmonary artery was severely dilated 
• The left heart was normal 
• Doppler ultrasound of the lower limbs and 
abdomen did not show evidence of thrombi; 
however, lymph nodes were noted in the porta 
hepatis and para‐aortic region 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167281/ 
Case Report 5.10. 
• The computed tomography (CT) pulmonary 
angiogram confirmed features of pulmonary 
hypertension, while also revealing extensive 
mediastinal adenopathy 
• Significantly, the CT scan did not show 
evidence of intraluminal pulmonary thrombi 
or features of parenchymal lung disease 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167281/ 
Case Report 6.10. 
• An axial 
contrasted CT 
scan of the 
chest showing 
enlarged main 
pulmonary 
trunk suggesting 
pulmonary 
hypertension 
and extensive 
mediastinal 
lymphadenopath
y 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167281/ 
Case Report 7.10. 
• During the next 24 h, she developed cardiovascular instability 
characterized by recurrent discrete episodes of hypotension 
and hypoxia without arrhythmia, necessitating intermittent 
non‐invasive positive pressure ventilation and fluid resuscitation 
with good inter‐episode clinical response 
• After the second such episode, she was thrombolysed for 
suspected new massive pulmonary thromboembolism and admitted 
to the intensive care unit 
• On the 65th hour from hospital admission and after a period of 
clinical stability, she suffered a recurrent episode of 
hypotension and hypoxia, and demised despite prolonged 
resuscitation 
• A post‐mortem examination macroscopically showed generalized 
lymphadenopathy and prominent small pulmonary vessels 
• Microscopic examination of the enlarged mediastinal lymph nodes 
showed a poorly differentiated adenocarcinoma, which was also 
found in the peri‐pancreatic and peri‐adrenal soft tissue and 
invading the diaphragm. 
 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167281/ 
Case Report 8.10. 
Examination of the lungs demonstrated multiple organized tumor emboli occluding the pulmonary vessels 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167281/ 
Case Report 9.10. 
 Immunohistochemistry performed was positive 
for CK20 and negative for CK7, which is typical 
for colorectal adenocarcinomas 
 Macroscopic examination of the gastrointestinal 
system, however, failed to localize a macroscopic 
lesion in the gastrointestinal tract 
 In addition, CDX‐2 (usually positive in colorectal 
adenocarcinomas) tested negative in this patient 
 The post‐mortem was unable to identify 
conclusively a primary location for this 
disseminated malignancy 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167281/ 
Case Report: Conclusion 10.10. 
 Pulmonary tumor emboli is typically an end‐stage 
manifestation of malignancy, and the prognosis 
with or without therapy is generally poor after 
onset of symptoms 
 The patient was a young, previously healthy 
female with no suggestive medical or family 
history 
 She presented with rapid onset fatal cor 
pulmonale due to pulmonary tumor embolism 
from an occult carcinoma of an unknown origin, 
which is extremely rare 
 Most cases of pulmonary tumor embolism occur 
in patients with established malignancies 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167281/ 

